QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.107.017251v1 35/12/2143    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Omura, K. Articles by Nagata, O. Search for Related Content PubMed PubMed Citation Articles by Omura, K. Articles by Nagata, O.

Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor

Research Laboratories 2 (K.O., T.N., T.I., O.N.) and Research Laboratories 1 (T.S.), Fuji Yakuhin Co., Ltd., Nishi-ku, Saitama, Japan

In humans, orally administered 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051) is excreted mainly as triazole N₁- and N₂-glucuronides in urine. It is important to determine the enzyme(s) that catalyze the metabolism of a new drug to estimate individual differences and/or drug-drug interactions. Therefore, the characterization and mechanism of these glucuronidations were investigated using human liver microsomes (HLMs), human intestinal microsomes (HIMs), and recombinant human UDP-glucuronosyltransferase (UGT) isoforms to determine the UGT isoform(s) responsible for FYX-051 N₁- and N₂-glucuronidation. FYX-051 was metabolized to its N₁- and N₂-glucuronide forms by HLMs, and their K_m values were 64.1 and 72.7 µM, respectively; however, FYX-051 was scarcely metabolized to its glucuronides by HIMs. Furthermore, among the recombinant human UGT isoforms, UGT1A1, UGT1A7, and UGT1A9 catalyzed the N₁- and N₂-glucuronidation of FYX-051. To estimate their contribution to FYX-051 glucuronidation, inhibition analysis with pooled HLMs was performed. Mefenamic acid, a UGT1A9 inhibitor, decreased FYX-051 N₁- and N₂-glucuronosyltransferase activities, whereas bilirubin, a UGT1A1 inhibitor, did not affect these activities. Furthermore, in the experiment using microsomes from eight human livers, the N₁- and N₂-glucuronidation activity of FYX-051 was found to significantly correlate with the glucuronidation activity of propofol, a specific substrate of UGT1A9 (N₁: r² = 0.868, p < 0.01; N₂: r² = 0.775, p < 0.01). These results strongly suggested that the N₁- and N₂-glucuronidation of FYX-051 is catalyzed mainly by UGT1A9 in human livers.

This article has been cited by other articles:

				S. Kaivosaari, P. Toivonen, O. Aitio, J. Sipila, M. Koskinen, J. S. Salonen, and M. Finel Regio- and Stereospecific N-Glucuronidation of Medetomidine: The Differences between UDP Glucuronosyltransferase (UGT) 1A4 and UGT2B10 Account for the Complex Kinetics of Human Liver Microsomes Drug Metab. Dispos., August 1, 2008; 36(8): 1529 - 1537. [Abstract] [Full Text] [PDF]